ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,0877
0,02%
Bitcoin
66.699,30
0,64%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Johnson & Johnson (0R34)

  7. Johnson & Johnson (0R34) News

0R34

Johnson & Johnson (0R34)

Johnson & Johnson
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0R34
DatumZeitQuelleÜberschriftSymbolFirma
01/05/202415h17Alliance NewsAlliance NewsTOP NEWS: J&J proposes USD6.48 billion settlement of cancer lawsuitsLSE:0R34Johnson & Johnson
16/04/202412h54Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson upgrades guidance on swing to earningsLSE:0R34Johnson & Johnson
05/04/202413h02Alliance NewsAlliance NewsTOP NEWS: J&J swoops for Shockwave Medical in USD13.1 billion dealLSE:0R34Johnson & Johnson
25/03/202419h28Alliance NewsAlliance NewsIN BRIEF: J&J submits US premarket approval application for VaripulseLSE:0R34Johnson & Johnson
18/03/202412h10Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson receives FDA recommendation for CarvyktiLSE:0R34Johnson & Johnson
23/02/202419h32Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson gets EMA nod for Carvykti in myelomaLSE:0R34Johnson & Johnson
02/02/202407h22Alliance NewsAlliance NewsTOP NEWS: US sends drugmakers initial offers in Medicare price talksLSE:0R34Johnson & Johnson
23/01/202412h41Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson eyes future growth; 2023 sales riseLSE:0R34Johnson & Johnson
19/01/202422h34Alliance NewsAlliance NewsIN BRIEF: J&J gets US FDA approval for cancer treatment BalversaLSE:0R34Johnson & Johnson
05/12/202314h24Alliance NewsAlliance NewsTOP NEWS: J&J expects strong long-term growth in three key driversLSE:0R34Johnson & Johnson
23/10/202313h03Alliance NewsAlliance NewsJ&J report slew of positive trial results focused on various cancersLSE:0R34Johnson & Johnson
17/10/202312h46Alliance NewsAlliance NewsTOP NEWS: J&J raises full-year sales outlook after "solid" quarterLSE:0R34Johnson & Johnson
06/10/202317h52Alliance NewsAlliance NewsIN BRIEF: J&J applies for indication extension to EMA for RybrevantLSE:0R34Johnson & Johnson
03/10/202318h00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0R34Johnson & Johnson
07/09/202307h50Alliance NewsAlliance NewsJ&J's Janssen ends Phase 3 MACiTEPH study evaluating macitentanLSE:0R34Johnson & Johnson
30/08/202318h07Alliance NewsAlliance NewsTOP NEWS: J&J forecasts strong growth in earnings after Kenvue splitLSE:0R34Johnson & Johnson
10/08/202322h34Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson's blood cancer therapy approved by FDALSE:0R34Johnson & Johnson
20/07/202313h30Alliance NewsAlliance NewsTOP NEWS: J&J ups full-year guidance after "robust" second quarterLSE:0R34Johnson & Johnson
30/05/202317h48Alliance NewsAlliance NewsJ&J seeks FDA approval for pulmonary arterial hypertension treatmentLSE:0R34Johnson & Johnson
09/05/202321h23Alliance NewsAlliance NewsJ&J says Tremfya data shows positive results for ulcerative colitisLSE:0R34Johnson & Johnson
04/05/202313h41Alliance NewsAlliance NewsIN BRIEF: J&J prices subsidiary Kenvue's NYSE initial public offeringLSE:0R34Johnson & Johnson
01/05/202308h51Alliance NewsAlliance NewsJohnson & Johnson reports first results from TAR-200 studyLSE:0R34Johnson & Johnson
18/04/202313h06Alliance NewsAlliance NewsTOP NEWS: J&J swings to first quarter loss due to litigation costsLSE:0R34Johnson & Johnson
05/04/202307h01Alliance NewsAlliance NewsJ&J proposes USD8.9 billion settlement of talc cancer claimsLSE:0R34Johnson & Johnson
04/04/202322h57Alliance NewsAlliance NewsIN BRIEF: J&J subsidiary re-files for bankruptcy amid talc claimsLSE:0R34Johnson & Johnson
17/03/202319h04Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson notes positive data for psoriasis drugLSE:0R34Johnson & Johnson
24/01/202313h33Alliance NewsAlliance NewsTOP NEWS: J&J fourth-quarter revenue falls on fewer Covid jab salesLSE:0R34Johnson & Johnson
05/01/202310h06Alliance NewsAlliance NewsJohnson & Johnson's consumer health unit files to go publicLSE:0R34Johnson & Johnson
09/12/202217h51Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson submits licence application to FDALSE:0R34Johnson & Johnson
01/12/202212h37Alliance NewsAlliance NewsJohnson & Johnson appoints Chief Executive Joaquin Duato as new chairLSE:0R34Johnson & Johnson
 Showing the most relevant articles for your search:LSE:0R34

Kürzlich von Ihnen besucht

TG
41K
Quebec Rare Earth Elements
NASDAQ
IPLDP
Interstate Power and Light
TG
1VV
VinaCapital Vietnam Oppo...
BIT
UC4KTZ
Unicredit Bank
EU
NSCNL00NAMU8
Amundi
NASDAQ
BETR
Better Home and Finance
COIN
NYAN-2ETH
Nyan V2
TSXV
AUTO
Carbeeza
TG
0QY
QYOU Media
COIN
RAKUCETH
Raku Coin
EU
CDCKF
Caisse des Depots et Con...
BIT
UC69D0
Unicredit Bank
COIN
OSAKETH
Osaka Protocol
TG
DTUR
U.S. Gold
TG
EIP
Elliptic Laboratories ASA
TG
41X
Ardelyx
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten